In June 2023, two major international academic events in the field of hematology were held successively. The 28th European Hematology Association Annual Meeting (EHA) took place from June 8th to 11th in Frankfurt, Germany, in a hybrid format, both online and offline. The EHA Annual Meeting is one of the largest international conferences in the field of hematology globally, attracting over 10,000 professionals from more than 100 countries each year. World-class hematologists gather to share the latest scientific research and clinical research outcomes in the field of hematology; Meanwhile, the 17th International Conference on Malignant Lymphoma (ICML) was held from June 13th to 17th in Lugano, Switzerland, gathering representatives of doctors and scientists from all over the world to share and discuss the latest research findings on lymphoma. The abstract titles of the selected research have been announced on the official websites of EHA and ICML.

The GoBroad team has persisted in innovation since its establishment in 2017, having reported Chinese scientific research outcomes at top international hematology conferences more than a hundred times, delivering an impressive report card in the global field of hematology. This time, the expert team from  GoBroad Medical Institute of Hematology (Beijing Center),Beijing GoBroad Boren Hospital, continues to focus on the CAR-T treatment of refractory and relapsed hematologic malignancies, as well as the combination of CAR-T with hematopoietic stem cell transplantation, with 12 studies selected for presentation at EHA2023 (including 1 conference oral presentation, 6 poster presentations, and 5 paper abstracts), and 2 studies selected for oral presentations at ICML2023. This marks another splendid appearance of the GoBroad Boren team on the world stage of hematology.

Among the 14 research reports selected by the GoBroad Boren team this time, covering clinical, diagnostic, and other areas, all research and innovative breakthroughs originate from the urgent treatment needs of patients. With innovative thinking breaking through the traditional treatment "ceiling" and optimizing strategies to make classic methods more enduring, ultimately benefiting more patients extensively, this is also the consistent academic purpose and goal of the GoBroad team.

The expert team of Beijing GoBroad Boren Hospital always progresses in scientific research and innovation, gracing the international gatherings in the field of hematology, and conveying the voice of China's clinical and scientific research to the world; each difficult breakthrough and pursuit of excellence aims to improve treatment outcomes, bringing hope of life to numerous patients with hematologic diseases.